| Toxicities and outcomes of 616 ibrutinib-treated patient... |
69 |
| Daratumumab plus bortezomib and dexamethasone versus bor... |
67 |
| Daratumumab plus lenalidomide and dexamethasone versus l... |
60 |
| Gemtuzumab ozogamicin for de novo acute myeloid leukemia... |
43 |
| The Khorana score for prediction of venous thromboemboli... |
40 |
| Cancer in the National Cancer Institute inherited bone m... |
33 |
| Real-world outcomes and management strategies for veneto... |
29 |
| Sustained efficacy and detailed clinical follow-up of fi... |
28 |
| From transplant to novel cellular therapies in multiple ... |
28 |
| Thrombopoietin receptor agonists: ten years later |
27 |
